adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant MTC who require systemic therapyadult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion–positive thyroid carcinoma who require systemic therapy and who are radioactive iodine-refractory. Here, RET is linked to medullary thyroid gland carcinoma.